Latest Breaking News On - North american antiepileptic drug - Page 7 : comparemela.com

Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual Meeting

/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations,.

United statesCounty south dublinUnited kingdomGreat britainRobert iannoneKristin bhavnaniAndrean flynnCommission file noEpidiolex caregiver surveyAmerican epilepsy societyJazz pharmaceuticalsArts allianceGw pharmaceuticalsTuberous sclerosis allianceEuropean unionTs alliance website

Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer s Disease, Insomnia and Epilepsy

Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer s Disease, Insomnia and Epilepsy Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimer s disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome News provided by Share this article Share this article WOODCLIFF LAKE, N.J., April 16, 2021 /PRNewswire/ Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company s deep neurology pipeline and portfolio, including Alzheimer s disease, insomnia and epilepsy, will be presented at the 73 rd Annual Meeting of the American Academy of Neurology (AAN), taking place virtually from April 17-22, 2021.

United statesNew jerseyNorth carolinaGary zammitShau yu lynchAlzheimers dementRyan husniGenevieve meierCarmen castrillo vigueraCraig chepkeIvan cheungChris vancheriMichael irizarryRussell rosenbergRakeh jainRohit shankar

ONTOZRY® (Cenobamate) Receives European Commission Approval for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults

ONTOZRY® (Cenobamate) Receives European Commission Approval for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomAngelini pharmaPierluigi antonelliDaniela poggioGlobal communicationsCo ltdHead of communicationsSk groupSk biopharmaceuticals co ltdMental healthEuropean commissionDrug administrationSk life science incAngelini groupYsk holdings

Cenobamate Receives Positive CHMP Opinion for Adjunctive Treatment of Focal-Onset (Partial-Onset) Seizures

Share this article PANGYO, GYEONGGI PROVINCE, Korea, Jan. 29, 2021 /PRNewswire/ SK Biopharmaceuticals announced that the European Medicines Agency s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of cenobamate for the adjunctive treatment of focal-onset (partial-onset) seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-seizure medications (ASMs). The European Commission (EC), which is authorized to approve medicines in the European Union, is expected to issue its decision within approximately 67 days of receipt of the CHMP opinion. SK Biopharmaceuticals and Arvelle Therapeutics entered into a licensing agreement in 2019 for Arvelle to commercialize SK Biopharmaceuticals cenobamate in Europe. Cenobamate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of partial-onset (focal-ons

United statesUnited kingdomJuan vergezNick jamesAngelini pharmaPierluigi antonelliDaniela poggioChloe nicholsSk groupMental healthArvelle therapeutics international gmbEuropean unionCommittee for medicinal products human useAtrio healthHead of communicationsSk biopharmaceuticals co ltd